NCI-9742-NIVO-NPC

NCT02105636 📎

Regimen

Experimental
Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity
Control
none

Population

Recurrent or metastatic NPC with at least one prior line of therapy; international multicenter including Asian centers; unselected for PD-L1

Key finding

This Western-led NCI study demonstrated nivolumab has single-agent antitumor activity in recurrent/metastatic NPC, with a 20.5% ORR and a 1-year OS of 59% that compared favorably with historical chemotherapy data. The study noted no correlation with PD-L1 expression, but HLA class I loss was associated with better PFS — a unique biomarker finding in NPC. This trial, alongside KEYNOTE-028, defines the early Western ICI monotherapy signal in NPC.

Source: PMID 29584545

Timeline

    Guideline citations

    • NCCN NPC (p.43)